Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: A randomized, open-label, three-period crossover study in healthy volunteers

Clinical Therapeutics

Volumn 32, Issue 6, 2010, Pages 1165-1177

  Berges, Alienor ^a   Walls, Christine ^a   Lener, Shelly E ^b   McDonald, Susan A ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Migraine; Pharmacokinetics; Rescue medication; Subcutaneous sumatriptan injection; Sumatriptan naproxen sodium

Indexed keywords

NAPROXEN PLUS SUMATRIPTAN; SUMATRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NAPROXEN; SEROTONIN AGONISTS; SUMATRIPTAN; YOUNG ADULT;

EID: 77954650426     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.06.014     Document Type: Article

References (25)

1. Solomon S Major therapeutic advances in the past 25 years. Headache. 2007, 47(Suppl 1):S20-S22.
2. Ramadan NM Targeting therapy for migraine: What to treat?. Neurology. 2005, 64(Suppl 2):S4-S8.
3. Cady RK, Freitag FG, Mathew NT, et al. Allodynia-associated symptoms, pain intensity and time to treatment: Predicting treatment response in acute migraine intervention. Headache. 2009, 49:350-363.
4. Silberstein SD, Mannix LK, Goldstein J, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine [published correction appears in Neurology. 2009;72:1369]. Neurology. 2008, 71:114-121.
5. Newman LC, Cady RK, Landy S, et al. Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan. Int J Clin Pract. 2008, 62:1889-1899.
6. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptannaproxen for acute treatment of migraine: A randomized trial. JAMA. 2007, 297:1443-1454.
7. Scholpp J, Schellenberg R, Moeckesch B, Banik N Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia. 2004, 24:925-933.
8. Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 Randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003, 78:1214-1222.
9. Loder E, Freitag FG, Adelman J, et al. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: Results of a large double-blind placebo-controlled trial. Curr Med Res Opin. 2005, 21:381-389.
10. Lipton RB, Dodick DW, Adelman JU, et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia. 2009, 29:826-836.
11. Dodick D, Lipton R, Silberstein S, et al. Opportunity for early intervention in a clinical trial setting. Cephalalgia. 2007, 27:1196. Abstract.
12. IMITREX (sumatriptan succinate) injection [prescribing information] Accessed April 13, 2009. http://us.gsk.com/products/assets/us_imitrex_injection.pdf.
13. TREXIMET (sumatriptan and naproxen sodium) tablets [prescribing information] Accessed April 13, 2009. http://us.gsk.com/products/assets/us_treximet.pdf.
14. IMITREX (sumatriptan succinate) tablets [prescribing information] Accessed April 13, 2009. http://us.gsk.com/products/assets/us_imitrex_tablets.pdf.
15. ANAPROX (naproxen sodium) tablets [prescribing information] Accessed May 5, 2010. http://www.rocheusa.com/products/naprosyn/pi.pdf.
16. Wendt J, Cady R, Singer R, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther. 2006, 28:517-526.
17. Mushet GR, Cady RK, Baker CC, et al. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Clin Ther. 1996, 18:687-699.
18. Hood S, Birnie D, Hillis S The haemodynamic effects of subcutaneous sumatriptan, a 5HT1-receptor agonist. Br J Clin Pharmacol. 1997, 43:327-328.
19. Haberer LJ, Walls CM, Lener SE, et al. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2010, 50:357-373.
20. Guidance for Industry: Bioanalytical Method Validation US Dept of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, Center for Veterinary MedicineCenter for Veterinary Medicine, Accessed January 23, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
21. An open-label, randomised, two-period, crossover study to assess the safety, tolerability and pharmacokinetics of the 3 mg STATdose administered two hours after a single IMITREX 100 mg tablet relative to two 6 mg STATdose injections administered one hour apart in healthy volunteers GlaxoSmithKline, Accessed May 24, 2010. http://www.gsk-clinicalstudyregister.com/files/pdf/3080.pdf.
22. Armitage P, Berry G Statistical Methods in Medical Research 1987, Blackwell Scientific Publications, Oxford, UK. 2nd ed.
23. Rowland M, Tozer TN Clinical Pharmacokinetics: Concepts and Applications 1995, Williams & Wilkins, Baltimore, Md. 3rd ed.
24. Salonen R, Scott A Triptans: Do they differ?. Curr Pain Headache Rep. 2002, 6:133-139.
25. Fox AW Onset of effect of 5-HT1 B/1 D agonists: A model with pharmacokinetic validation. Headache. 2004, 44:142-147.